АПЛАСТИЧЕСКАЯ АНЕМИЯ
Аннотация
Апластическая анемия
Библиографические ссылки
1. Руководство по гематологии. Под ред. А.И. Воробьева издание третье). М.: Ньюдиамед, 2005. - Т.3. - 416 с.
2. Ehrlich P. Farbanalytische Untersuchungen zur Histologie und Klinik des BIutes. — Berlin, 1888.
3. Issaragrisil S., Kaufman D.W., Anderson T., et al. The epidemiology of aplastic anemia in Thailand. Blood 2006;107:1299—307.
4. Camitta B. M. Aplastic anemia. Pathogenesis, diagnosis,treatment, and prognosis.// N. Engl. J. Med. 306:645 (Part I), 712 Part II), 1982.
5. Абдулкадыров К.М. Клиническая гематология.Справочник. Москва-СПб.: Питер, 2006, 448 с.
6. Виктор Хоффбранд, Джон Петит. Гематология. Атлас-справочник. Пер.с англ. М.., «Практика», 2007.- 408 с.
7. Kim S.Y., Lee J.W., Lee S.E., et al. The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis. Genes Chromosomes Cancer 2010;49(9):844-850.
8. Locasciulli A., Oneto R., Bacigalupo A., et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007;92:11—8.
9. Marsh J.C., Socie G., Schrezenmeier H., et al. Prospective phase II pilot study of rabbit antithymocyte globulin (ATG, thy-moglobulin) with ciclosporin for patients with acquired aplastic anemia and matched pair analysis with patients treated with horse ATG (lymphoglobulin) and ciclosporin: a study from the EBMT Severe Aplastic Anemia Working Party (RATGAA07) [abstract]. Blood (ASH Annual Meeting Abstracts) 2011;117: 2408.
10. Passweg J.R., Marsh J.C.W. Aplastic anemia: first-linetreatment by immunosuppression and sibling marrow transplantation. ASH Education Program Book 2010;2010:36-42.
11. Раимжанов А.Р. Апластическая анемия и горныйклимат, Бишкек, 2002, 304 с.
12. Rosenfeld S., Follmann D., Nunez O., Young N.S. Antithy-mocyte globulin and cyclospo-rine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289(9):1130-1135.
13. Tichelli A., Schrezenmeier H., Socié G., et al. A ran-domized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011;117(17):4434-4441.
14. Frickhofen N., Heimpel H., Kaltwasser J.P., Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236—42.
15. Hochsmann B., Neher C., Germing U., et al. Therapy ofacquired aplastic anemia (AA) with rabbit antithymocyte globulin (rATG): a retrospective analysis by the Working Gro-up on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO) [abstract]. Blood (ASH Annual Meeting Abstracts) 2011;117: 3434.
16. Scheinberg P., Nunez O., Weinstein B., et al Horse versusrabbit antithymocyte globulin in acquired aplastic anemia. N. Engl. J. Med. 2011;365(5):430-438.
17. Vallejo C., Montesinos P.,Rosell A., et al. Comparison between lymphoglobulin- and thy-moglobulin-based immunosuppressive therapy as first-line treatment for patients with aplastic anemia [abstract]. Blood (ASH Annual Meeting Abstracts)2009;114(22):3194.
18. Young N.S., Bacigalupo A., Marsh J.C. Aplastic anemia: pathophysiology and treatment. Biology of blood and marrow transplantation. J. Am. Soc. Blood. Marrow Transplant. 2010;16 1 Suppl:S119-S125.
